Not indicated for use in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Semaglutide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.
February 2026: The UK Medicines and Healthcare Products Regulatory Agency (MHRA) updated product information regarding the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.
The UK MHRA advises that patients taking semaglutide who notice a change in their eyesight, such as sudden impairment to their vision, or if their eyesight gets worse very quickly in one or both eyes, should urgently attend eye casualty (if available in the area) or A&E.
An oral formulation of semaglutide and sodium salcaprozate (an intestinal permeation enhancer) is available in the United States and Europe.
WARNING: RISK OF THYROID C-CELL TUMORS
IN RODENTS, SEMAGLUTIDE CAUSES THYROID C-CELL TUMORS. IT IS UNKNOWN WHETHER SEMAGLUTIDE CAUSES THYROID C-CELL TUMORS, INCLUDING MEDULLARY THYROID CARCINOMA (MTC), IN HUMANS AS THE HUMAN RELEVANCE OF SEMAGLUTIDE-INDUCED RODENT THYROID C-CELL TUMORS HAS NOT BEEN DETERMINED. SEMAGLUTIDE IS CONTRAINDICATED IN PATIENTS WITH A PERSONAL OR FAMILY HISTORY OF MTC OR IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA SYNDROME TYPE 2. COUNSEL PATIENTS REGARDING THE POTENTIAL RISK OF MTC AND SYMPTOMS OF THYROID TUMORS.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
